$TWST

Cho Dennis sold $28K of TWST

Cho Dennis (See Remarks) sold 402 shares of Twist Bioscience Corp (TWST) at $69.84 on 2026-06-08.

Original reporting
SEC EDGAR · Cho Dennis
Published Jun 10, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 8:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TWST
Neutral
medium confidence
Mentioned
$TWST
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TWSTNeutralLow
01

Why it matters

Because it’s a routine insider transaction without accompanying corporate news, it mainly affects sentiment rather than valuation drivers.

02

Market read

Traders may note the insider selling signal, but the disclosed value is modest and not a standalone catalyst.

03

What to watch

The transaction size is small relative to typical institutional flows, and the filing timing may not coincide with any fundamental catalyst.

Relevance 3/10Novelty 2/10Timing: Filed 2026-06-10 for a 2026-06-08 sale

Background

The article is a primary-source SEC Form 4 disclosure reporting an officer’s open-market sale of Twist Bioscience shares.

Company-level read

Ticker impact

$TWSTNeutralMedium confidence
Context

Twist Bioscience insider Dennis Cho filed an open-market sale of 402 shares at $69.8442 on 2026-06-08 (Form 4).

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The disclosure is a routine Form 4 insider transaction with modest dollar value ($28k) and no stated linkage to a new corporate event.

Market effects

No clear read-across to biotech tools/insider behavior beyond routine governance signals.

None.

None.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs; the lack of a 10b5-1 plan doesn’t necessarily imply bearish conviction.

Key entities

  • Twist Bioscience Corp

    Subject of the Form 4 insider sale disclosure.

  • Dennis Cho

    Officer who sold 402 shares on 2026-06-08.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$TWSTHigh

Twist Bioscience Stock Jumps On Lilly AI Drug Discovery Deal

Twist Bioscience (TWST) stock rose 9.74% after announcing a deal with Eli Lilly for AI-driven drug discovery. The company reported $118.4M in Q3 revenue, up 23% YoY, with improved gross margins. TWST remains unprofitable but expects adjusted EBITDA breakeven in Q4. The Lilly partnership validates its technology and business model, according to the company.

$TWSTHighAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Lifts Outlook

Twist Bioscience (TWST) stock rose 9.94% after announcing a deal with Eli Lilly to supply data for its AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year guidance to $456–457M. UBS initiated coverage with a Neutral rating and $144 price target. TWST is targeting adjusted EBITDA breakeven in Q4 FY26.

$TWSTMedAI 8/10

Twist Bioscience Stock Jumps As Lilly AI Deal Fuels Growth Story

Twist Bioscience (TWST) stock rose 9.94% after reporting Q3 FY26 revenue of $118.4M, up 23% YoY, and raising full-year guidance to $456–$457M. The company announced an AI collaboration with Eli Lilly, boosting its valuation. TWST has 14 consecutive quarters of growth, 52.8% gross margin, and targets adjusted EBITDA breakeven in Q4 FY26.

$TWSTHighAI 8/10

Twist Bioscience TWST Stock Jumps On Lilly AI Deal

Twist Bioscience (TWST) stock rose 11.43% after announcing a deal with Eli Lilly to provide antibody characterization data for Lilly's AI/ML TuneLab platform. The company reported Q3 FY26 revenue of $118.4M, up 23% YoY, and raised full-year revenue guidance to $456–457M. UBS initiated coverage with a Neutral rating and a $144 price target.